BN80927 in Patients With Advanced Malignant Solid Tumors
The purpose of this study was to determine the maximum tolerated dose and the recommended dose of BN80927 in patients with advanced malignant solid tumors.
Malignant Solid Tumour
DRUG: BN80927
Maximum tolerated dose determined by incidence of dose limiting toxicity., During cycle 1, up to 3 weeks|Recommended dose determined by incidence of dose limiting toxicity., During cycle 1, up to 3 weeks
Tumour response assessment according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria., Baseline, week 3 of cycle 2, then on alternate cycles of treatment (maximum 10 cycles, up to 30 weeks)|Cmax, 72 hours post-dose in treatment cycle 1 and 2 (each cycle is 21 days)|Area Under Curve, 72 hours post-dose in treatment cycle 1 and 2 (each cycle is 21 days)|Tmax, 72 hours post-dose in treatment cycle 1 and 2 (each cycle is 21 days)|T1/2, 72 hours post-dose in treatment cycle 1 and 2 (each cycle is 21 days)|Number of adverse events, Monitored weekly at all treatment cycles and the end of study visit. Maximum 10 treatment cycles, up to 30 weeks.
The purpose of this study was to determine the maximum tolerated dose and the recommended dose of BN80927 in patients with advanced malignant solid tumors.